[Treatment of alopecia areata totalis and maligna with Solvezink (author's transl)].
Study Design
- Тип исследования
- Clinical Trial (non-randomized/observational, retrospective)
- Размер выборки
- 284
- Вмешательство
- [Treatment of alopecia areata totalis and maligna with Solvezink (author's transl)]. Solvezink (zinc sulfate oral solution); dosage individualized
- Препарат сравнения
- Placebo
- Направление эффекта
- Positive
- Риск систематической ошибки
- High
Abstract
Treatment with Solvezink has been performed in 284 patients: 42 with alopecia areata, 106 with alopecia totalis (preserved axillar and pubic air as well as eyelashes and brows) and 136 with alopecia maligna. The duration of the treatment including maintenance therapy was up to 6 years. In patients with alopecia areata a state without relapse of 1 to 4 years was achieved in 42,8% of cases, in alopecia totalis and maligna a maintenance therapy was necessary to ensure a permanent regrowth of the hair. When applied correctly, Solvezink was well tolerated. The dosages and the treatment intervals of the treatment should be adjusted individually.
Кратко
Treatment with Solvezink was well tolerated and in patients with alopecia areata a state without relapse of 1 to 4 years was achieved in 42,8% of cases, in alopECia totalis and maligna a maintenance therapy was necessary to ensure a permanent regrowth of the hair.
Used In Evidence Reviews
Similar Papers
Nature · 2010
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.
Journal of the American Academy of Dermatology · 2006
The diagnosis and treatment of iron deficiency and its potential relationship to hair loss.
Clinical and experimental dermatology · 1989
Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study.
American journal of clinical dermatology · 2005
Dermatologic signs in patients with eating disorders.
Archives of biochemistry and biophysics · 2016
Zinc and skin biology.
Annals of dermatology · 2013